<DOC>
	<DOCNO>NCT01109680</DOCNO>
	<brief_summary>A Single Center , Open-Label Study quantify metabolite [ 14C ] -Neramexane plasma urine Healthy Male Subjects</brief_summary>
	<brief_title>A Single Center , Open-Label Study Quantify Metabolites 14C-Neramexane Plasma Urine Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Aged 55 65 year inclusive BMI 1829 kg/m2 ( inclusive ) body weight ≥50 ≤90 kg All ethnicity , Fitzpatrick type &lt; IV ( see appendix 2 ) Willing able provide write informed consent inform requirement restriction study Healthy adult male subject , able read , write fully understand Dutch language History clinically relevant allergy know hypersensitivity Neramexane/Memantine/Amantadine derivates Exposure another investigational agent within last two month first drug administration Administration radiolabeled substance exposure significant radiation ( e.g . serial Xray CT scan etc . ) within last 12 month . Xrays spiral CT scan extremity allow . Lack suitability study Any evidence significant cardiovascular , pulmonary , renal , hepatic , gastrointestinal , endocrinological , metabolic , psychiatric , neurologic acute chronic disease Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence pharmacokinetics investigational medicinal product ( e.g . cholecystectomy , active gastric ulcer , etc . ) Clinically relevant acute chronic infection , observe within 4 week first drug administration History malignancy , except basal cell carcinoma Any clinically relevant deviation clinical laboratory assessment deem investigator Abnormalities 12lead ECG ( screen ) discretion investigator Merz scientific expert clinical relevant might affect study objective Systolic blood pressure &lt; 95 mmHg &gt; 155 mmHg diastolic blood pressure &lt; 50 mmHg &gt; 95 mmHg supine position Pulse rate &lt; 45 &gt; 100 beat per minute History alcohol drug dependence Alcohol consumption average weekly intake excess 21 unit alcohol ( one unit alcohol equal glass beer 300 mL , glass wine 125 mL , measure spirit 25 mL ) within last year Regular large caffeine consumption average 6 cup coffee and/or tea per day 1 L caffeinecontaining beverage per day within last year Use prescribe medication 4 week prior first administration IMP ( except paracetamol , maximum 2 g/day ) . Thyroid hormone substitution allow ) Regular use overthecounter drug 4 week prior first administration IMP . Occasional use OTC drug ( except paracetamol , maximum 2 g/day ) 2 week prior first administration IMP Use food , food supplement medication know induce inhibit CYP3A4 cytochrome P450 enzymes within two week first drug administration e.g . grapefruit , St. Johns wort Consume xanthine derivates ( include caffeine ) within two day first drug administration Smokers exsmokers stop less 6 month , user snuff , nicotine replacement chew tobacco Blood donation 450 mL within 60 day first drug administration Positive result serology test Positive drug screen alcohol test Subject employee direct relative employee CRO Merz Pharmaceuticals Lack ability willingness give inform consent Lack willingness inability cooperate adequately Vulnerable subject ( e.g . person keep detention ) Anticipated nonavailability study visits/procedures</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>